)
)
)
BIOIO
.png)
BIOIO is a therapeutics company developing first-in-class gerotherapies for conditions like type II diabetes. Lead program, BIOIO-1001, is a dual insulin/GLP-1 sensitizer.
What is your next catalyst (value inflection) update?
DC nomination for BIOIO-1001
Year Founded
2023
Lead Product in Development
BIOIO-1001 - a dual Insulin and GLP-1 sensitizer for type II diabetes and related co-morbidities.
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
CEO/Top Company Official
Tim Peterson
When you expect your next catalyst update?
July 2026
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
